Ishihara K, Yamazaki N, Asano K
Department of Dermatology, National Cancer Center Hospital, Tokyo, Japan.
Gan To Kagaku Ryoho. 1993 Aug;20(10):1287-92.
Malignant melanoma is among the malignant tumors which still have the poorest prognosis. Thus, malignant melanoma of stage II and the more advanced stages. At present, chemotherapeutic combinations used as the first choice in Japan are two regimens of postoperative adjuvant therapy for stage II and III patients, that aim at preventing recurrence. One of the regimens is a DAV combination (Dacarbazine, ACNU, vincristine), and another is PAV combination (Pepleomycin, ACNU, vincristine). For stage IV patients, the major therapeutic procedure is a CDV combination (cisplatin, dacarbazine, vindesine). The efficacy of CDV treatment has been approximately 30 per cent in our studies. It has shown comparable effects for metastatic lesion in the lymph nodes, mucous membrane (nasal cavity) and brain, while lesions in other organs are largely unaffected in many instances. Studies of new drugs and combinations must be undertaken for the treatment of malignant melanoma.
恶性黑色素瘤是预后最差的恶性肿瘤之一。因此，II期及更晚期的恶性黑色素瘤更是如此。目前，在日本作为首选的化疗联合方案是针对II期和III期患者的两种术后辅助治疗方案，旨在预防复发。其中一种方案是DAV联合方案（达卡巴嗪、阿糖胞苷、长春新碱），另一种是PAV联合方案（博来霉素、阿糖胞苷、长春新碱）。对于IV期患者，主要治疗方法是CDV联合方案（顺铂、达卡巴嗪、长春地辛）。在我们的研究中，CDV治疗的有效率约为30%。它对淋巴结、黏膜（鼻腔）和脑转移灶显示出相当的效果，而在许多情况下，其他器官的病灶基本不受影响。必须开展针对恶性黑色素瘤治疗的新药及联合用药研究。
